STRATEGIC EYE – A column on current affairs – relating to global issues
Today, There Is Proliferation Of Knowledge About Biotechnology & Equipment Around The World
By Nivedita Das Kundu@
The Meeting of States Parties (MSP) to the 1972 Biological and Toxin Weapons Convention (BWC/BTWC) was held in Geneva during first week of December 2019.
The 1972 Biological Weapons Convention (BWC) serve as the norms against the use of biological weapons. Since the BWC entered into force in 1975, advances in biotechnology for use in the pharmaceutical, medical and agricultural industries have led to the rapid corresponding proliferation of knowledge and equipment across the globe.
Biological Weapons (BW) have been used as weapons of mass destruction. Various types of bacteria, pathogens, viruses etc are deliberately used to cause harm to humans, animals and plants.
With growing interest in using biotechnology for industrial uses such as bio-fabrication, bio-electronics, bio-sensors and even digital organisms and environmental remediation, the biotechnology industry undoubtedly continues to grow.
This growth implies that more nations and individuals will have access to dual-use of biotechnology that could be used for industrial purposes, economic development, curing disease or alternatively can be misused for malicious purposes.
In June 2018, German police arrested a Tunisian man in Cologne for trying to build a biological weapon using the deadly toxin, ricin. In October 2018, reports published that US agricultural program funded by DARPA (Defense Advanced Research Projects Agency) was working on bioweapons project. At the same time, Russia also claimed that the US had tested biological weapons in Georgia killing over 70 people.
Though China learned about the bio crisis through the Severe Acute Respiratory Syndrome (SARS) virus in 2003, nonetheless, concerns exist about the reporting and transparency by China regarding African Swine flu.
Even today, therapeutics including vaccine development continues to be elusive for many emerging diseases. For example, the therapeutic for Ebola, ZMapp, that is, the monoclonal antibody combination treatment used in the West African outbreak is still continuing to undergo testing. Despite calls for more rapid development, therapeutics still take over a decade to gain full licensure. Meanwhile, unproductive discussions about how and under what conditions to share biological defense capabilities globally as part of the BWC continue with little progress.
However, improved access to scientific knowledge, easier control over biological material and reduced cost of creating designer pathogens could entice state and non-state actors to experiment with biological weapons.
There have been attempts to explore and create technologies that could be weaponized by both state and non-state actors. However, global preparedness and response capabilities have been inadequate to address the range of biological threats that the world is facing today.
@Nivedita Das Kundu, Ph.D, is a subject expert and works on Weapons of Mass Destruction issues and concerns.